Phytomedicines in the Treatment of Migraine

A Letter to the Editor to this article was published on 30 April 2019


Migraine is a disabling neurovascular disorder with few targeted, tolerable and effective treatments. Phytomedicines, or plant-based medicinal formulations, hold great promise in the identification of novel therapeutic targets in migraine. Many patients also turn toward herbal and plant-based therapies for the treatment of their migraines as clinical and preclinical evidence of efficacy increases. Patients seek effective and tolerable treatments instead of or in addition to current conventional pharmacologic therapies. We review some phytomedicines potentially useful for migraine treatment—feverfew (Tanacetum parthenium), butterbur (Petasites hybridus), marijuana (Cannabis spp.), Saint John’s Wort (Hypericum perforatum) and the Damask rose (Rosa × damascena)—with respect to their mechanisms of action and evidence for treatment of migraine. The evidence for feverfew is mixed; butterbur is effective with potential risks of hepatotoxicity related to preparation; marijuana has not been shown to be effective in migraine treatment, and data are scant; Saint John’s Wort shows relevant physiological activity but is a hepatic enzyme inducer and lacks clinical studies for this purpose; the Damask rose when used in topical preparations did not show efficacy in one clinical trial. Other plant preparations have been considered for migraine treatment but most without blinded randomized, placebo-controlled trial evidence.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3

Adapted from Leimuranta et al. [103] with permission


  1. 1.

    Noseda R, Burstein R. Migraine pathophysiology: anatomy of the trigeminovascular pathway and associated neurological symptoms, cortical spreading depression, sensitization, and modulation of pain. Pain. 2013;154(Suppl 1):S44–53.

    CAS  Google Scholar 

  2. 2.

    Burstein R, Noseda R, Borsook D. Migraine: multiple processes, complex pathophysiology. J Neurosci Off J Soc Neurosci. 2015;35:6619–29.

    CAS  Google Scholar 

  3. 3.

    GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol. 2017;16:877–97.

    Google Scholar 

  4. 4.

    Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97:553–622.

    Google Scholar 

  5. 5.

    Rajapakse T, Pringsheim T. Nutraceuticals in migraine: a summary of existing guidelines for use. Headache. 2016;56:808–16.

    Google Scholar 

  6. 6.

    Headache Classification Committee of the International Headache Society. The international classification of headache disorders, 3rd edition. Cephalalgia Int J Headache. 2018;38:1–211.

    Google Scholar 

  7. 7.

    Olesen J, Burstein R, Ashina M, Tfelt-Hansen P. Origin of pain in migraine: evidence for peripheral sensitisation. Lancet Neurol. 2009;8:679–90.

    Google Scholar 

  8. 8.

    Levy D, Strassman AM. Mechanical response properties of A and C primary afferent neurons innervating the rat intracranial dura. J Neurophysiol. 2002;88:3021–31.

    Google Scholar 

  9. 9.

    Collado-Vázquez S, Carrillo JM. Cranial trepanation in the Egyptian. Neurol Barc Spain. 2014;29:433–40.

    Google Scholar 

  10. 10.

    Zargaran A, Borhani-Haghighi A, Faridi P, Daneshamouz S, Mohagheghzadeh A. A review on the management of migraine in the Avicenna’s Canon of Medicine. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2016;37:471–8.

    Google Scholar 

  11. 11.

    Abokrysha N. Ibn Sina (Avicenna) on pathogenesis of migraine compared with the recent theories. Headache. 2009;49:923–7.

    Google Scholar 

  12. 12.

    Heptinstall S, Awang DV, Dawson BA, Kindack D, Knight DW, May J. Parthenolide content and bioactivity of Feverfew (Tanacetum parthenium (L.) Schultz-Bip.). Estimation of commercial and authenticated feverfew products. J Pharm Pharmacol. 1992;44:391–5.

    CAS  Google Scholar 

  13. 13.

    Awang DVC. Prescribing therapeutic Feverfew (Tanacetum parthenium (L.) Schultz Bip., syn. Chrysanthemum parthenium (L.) Bernh.). Integr Med. 1998;1:11–3.

    Google Scholar 

  14. 14.

    Collier HO, Butt NM, McDonald-Gibson WJ, Saeed SA. Extract of feverfew inhibits prostaglandin biosynthesis. Lancet Lond Engl. 1980;2:922–3.

    CAS  Google Scholar 

  15. 15.

    Makheja AN, Bailey JM. A platelet phospholipase inhibitor from the medicinal herb feverfew (Tanacetum parthenium). Prostaglandins Leukot Med. 1982;8:653–60.

    CAS  Google Scholar 

  16. 16.

    Heptinstall S, White A, Williamson L, Mitchell JR. Extracts of feverfew inhibit granule secretion in blood platelets and polymorphonuclear leucocytes. Lancet Lond Engl. 1985;1:1071–4.

    CAS  Google Scholar 

  17. 17.

    Marles RJ, Kaminski J, Arnason JT, Pazos-Sanou L, Heptinstall S, Fischer NH, et al. A bioassay for inhibition of serotonin release from bovine platelets. J Nat Prod. 1992;55:1044–56.

    CAS  Google Scholar 

  18. 18.

    Brinker F. Herb contraindications and drug interactions. 3rd ed. Sandy: Eclectic Medical Publications; 2001.

    Google Scholar 

  19. 19.

    McGuffin M. American Herbal Products Association’s botanical safety handbook. Boca Raton: CRC Press; 1997.

    Google Scholar 

  20. 20.

    Pittler MH, Ernst E. Feverfew for preventing migraine. Cochrane Database Syst Rev. 2004;CD002286.

  21. 21.

    Wider B, Pittler MH, Ernst E. Feverfew for preventing migraine. Cochrane Database Syst Rev. 2015;4:CD002286.

  22. 22.

    Diener HC, Pfaffenrath V, Schnitker J, Friede M, Henneicke-von Zepelin H-H. Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention—a randomized, double-blind, multicentre, placebo-controlled study. Cephalalgia Int J Headache. 2005;25:1031–41.

    CAS  Google Scholar 

  23. 23.

    De Weerdt CJ, Bootsma HP, Hendriks H. Herbal medicines in migraine prevention randomized double-blind placebo-controlled crossover trial of a feverfew preparation. Phytomed Int J Phytother Phytopharm. 1996;3:225–30.

    Google Scholar 

  24. 24.

    Pfaffenrath V, Diener HC, Fischer M, Friede M, Henneicke-von Zepelin HH, Investigators. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis—a double-blind, multicentre, randomized placebo-controlled dose-response study. Cephalalgia Int J Headache. 2002;22:523–32.

    CAS  Google Scholar 

  25. 25.

    National Center for Complementary and Integrative Health. Butterbur [Internet]. 2017. Accessed 2018 Aug 15.

  26. 26.

    Taylor FR. Nutraceuticals and headache: the biological basis. Headache. 2011;51:484–501.

    Google Scholar 

  27. 27.

    Prieto J. Update on the efficacy and safety of Petadolex®, a butterbur extract for migraine prophylaxis. Bot Targets Ther. 2014;2:1–9.

    Google Scholar 

  28. 28.

    Brune K, Bickel D, Peskar BA. Gastro-protective effects by extracts of Petasites hybridus: the role of inhibition of peptido-leukotriene synthesis. Planta Med. 1993;59:494–6.

    CAS  Google Scholar 

  29. 29.

    Benemei S, De Logu F, Li Puma S, Marone IM, Coppi E, Ugolini F, et al. The anti-migraine component of butterbur extracts, isopetasin, desensitizes peptidergic nociceptors by acting on TRPA1 cation channel. Br J Pharmacol. 2017;174:2897–911.

    CAS  Google Scholar 

  30. 30.

    Benemei S, Fusi C, Trevisan G, Geppetti P. The TRPA1 channel in migraine mechanism and treatment. Br J Pharmacol. 2014;171:2552–67.

    CAS  Google Scholar 

  31. 31.

    Sheykhzade M, Smajilovic S, Issa A, Haunso S, Christensen SB, Tfelt-Hansen J. S-petasin and butterbur lactones dilate vessels through blockage of voltage gated calcium channels and block DNA synthesis. Eur J Pharmacol. 2008;593:79–86.

    CAS  Google Scholar 

  32. 32.

    Fiebich BL, Grozdeva M, Hess S, Hüll M, Danesch U, Bodensieck A, et al. Petasites hybridus extracts in vitro inhibit COX-2 and PGE2 release by direct interaction with the enzyme and by preventing p42/44 MAP kinase activation in rat primary microglial cells. Planta Med. 2005;71:12–9.

    CAS  Google Scholar 

  33. 33.

    Levy D, Burstein R, Kainz V, Jakubowski M, Strassman AM. Mast cell degranulation activates a pain pathway underlying migraine headache. Pain. 2007;130:166–76.

    CAS  Google Scholar 

  34. 34.

    Shimoda H, Tanaka J, Yamada E, Morikawa T, Kasajima N, Yoshikawa M. Anti type I allergic property of Japanese butterbur extract and its mast cell degranulation inhibitory ingredients. J Agric Food Chem. 2006;54:2915–20.

    CAS  Google Scholar 

  35. 35.

    Pringsheim T, Davenport WJ, Mackie G, Worthington I, Aubé M, Christie SN, et al. Canadian Headache Society guideline for migraine prophylaxis. Can J Neurol Sci J Can Sci Neurol. 2012;39:S1–59.

    Google Scholar 

  36. 36.

    Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E, et al. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1346–53.

    CAS  Google Scholar 

  37. 37.

    Lipton RB, Göbel H, Einhäupl KM, Wilks K, Mauskop A. Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. Neurology. 2004;63:2240–4.

    CAS  Google Scholar 

  38. 38.

    Diener HC, Rahlfs VW, Danesch U. The first placebo-controlled trial of a special butterbur root extract for the prevention of migraine: reanalysis of efficacy criteria. Eur Neurol. 2004;51:89–97.

    CAS  Google Scholar 

  39. 39.

    Mauskop A. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2013;80:868.

    Google Scholar 

  40. 40.

    Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, et al. EFNS guideline on the drug treatment of migraine–revised report of an EFNS task force. Eur J Neurol Off J Eur Fed Neurol Soc. 2009;16:968–81.

    CAS  Google Scholar 

  41. 41.

    The Pharmaceutical Journal. = false. Accessed 18 Nov 2018.

  42. 42.

    Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163:1344–64.

    CAS  Google Scholar 

  43. 43.

    Baron EP. Comprehensive review of medicinal Marijuana, Cannabinoids, and therapeutic implications in medicine and headache: what a long strange trip it’s been …. Headache. 2015;55:885–916.

    Google Scholar 

  44. 44.

    Battista N, Di Tommaso M, Bari M, Maccarrone M. The endocannabinoid system: an overview. Front Behav Neurosci. 2012;6:9.

    CAS  Google Scholar 

  45. 45.

    Iversen L. Cannabis and the brain. Brain J Neurol. 2003;126:1252–70.

    Google Scholar 

  46. 46.

    Palkovits M, Harvey-White J, Liu J, Kovacs ZS, Bobest M, Lovas G, et al. Regional distribution and effects of postmortal delay on endocannabinoid content of the human brain. Neuroscience. 2008;152:1032–9.

    CAS  Google Scholar 

  47. 47.

    Katona I, Freund TF. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med. 2008;14:923–30.

    CAS  Google Scholar 

  48. 48.

    Fan P. Cannabinoid agonists inhibit the activation of 5-HT3 receptors in rat nodose ganglion neurons. J Neurophysiol. 1995;73:907–10.

    CAS  Google Scholar 

  49. 49.

    Elsohly MA, Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci. 2005;78:539–48.

    CAS  Google Scholar 

  50. 50.

    Hillig KW, Mahlberg PG. A chemotaxonomic analysis of cannabinoid variation in Cannabis (Cannabaceae). Am J Bot. 2004;91:966–75.

    CAS  Google Scholar 

  51. 51.

    Ashton CH. Pharmacology and effects of cannabis: a brief review. Br J Psychiatry J Ment Sci. 2001;178:101–6.

    CAS  Google Scholar 

  52. 52.

    Williamson EM, Evans FJ. Cannabinoids in clinical practice. Drugs. 2000;60:1303–14.

    CAS  Google Scholar 

  53. 53.

    Hampson AJ, Grimaldi M, Lolic M, Wink D, Rosenthal R, Axelrod J. Neuroprotective antioxidants from marijuana. Ann N Y Acad Sci. 2000;899:274–82.

    CAS  Google Scholar 

  54. 54.

    Lichtman AH, Cook SA, Martin BR. Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement. J Pharmacol Exp Ther. 1996;276:585–93.

    CAS  Google Scholar 

  55. 55.

    Bushlin I, Rozenfeld R, Devi LA. Cannabinoid–opioid interactions during neuropathic pain and analgesia. Curr Opin Pharmacol. 2010;10:80–6.

    CAS  Google Scholar 

  56. 56.

    Akerman S, Holland PR, Goadsby PJ. Cannabinoid (CB1) receptor activation inhibits trigeminovascular neurons. J Pharmacol Exp Ther. 2007;320:64–71.

    CAS  Google Scholar 

  57. 57.

    McGeeney BE. Cannabinoids and hallucinogens for headache. Headache. 2013;53:447–58.

    Google Scholar 

  58. 58.

    Lochte BC, Beletsky A, Samuel NK, Grant I. The use of cannabis for headache disorders. Cannabis Cannabinoid Res. 2017;2:61–71.

    CAS  Google Scholar 

  59. 59.

    Russo E. Hemp for headache: an in-depth historical and scientific review of cannabis in migraine treatment. J Cannabis Ther. 2001;1:21–92.

    Google Scholar 

  60. 60.

    Noyes R, Baram DA. Cannabis analgesia. Compr Psychiatry. 1974;15:531–5.

    Google Scholar 

  61. 61.

    El-Mallakh RS. Marijuana and migraine. Headache. 1987;27:442–3.

    CAS  Google Scholar 

  62. 62.

    El-Mallakh RS. Migraine headaches and drug abuse. South Med J. 1989;82:805.

    CAS  Google Scholar 

  63. 63.

    Milstein SL, MacCannell K, Karr G, Clark S. Marijuana-produced changes in pain tolerance. Experienced and non-experienced subjects. Int Pharmacopsychiatry. 1975;10:177–82.

    CAS  Google Scholar 

  64. 64.

    Noyes R, Brunk SF, Avery DA, Canter AC. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther. 1975;18:84–9.

    Google Scholar 

  65. 65.

    Aggarwal SK. Cannabinergic pain medicine: a concise clinical primer and survey of randomized-controlled trial results. Clin J Pain. 2013;29:162–71.

    Google Scholar 

  66. 66.

    Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet Lond Engl. 2009;374:1383–91.

    CAS  Google Scholar 

  67. 67.

    Sachs J, McGlade E, Yurgelun-Todd D. Safety and toxicology of cannabinoids. Neurother J Am Soc Exp Neurother. 2015;12:735–46.

    CAS  Google Scholar 

  68. 68.

    Reece AS. Chronic toxicology of cannabis. Clin Toxicol Phila Pa. 2009;47:517–24.

    CAS  Google Scholar 

  69. 69.

    Vuralli D, Ayata C, Bolay H. Cognitive dysfunction and migraine. J Headache Pain. 2018;19:109.

    Google Scholar 

  70. 70.

    Crane NA, Schuster RM, Fusar-Poli P, Gonzalez R. Effects of cannabis on neurocognitive functioning: recent advances, neurodevelopmental influences, and sex differences. Neuropsychol Rev. 2013;23:117–37.

    Google Scholar 

  71. 71.

    Schweinsburg AD, Brown SA, Tapert SF. The influence of marijuana use on neurocognitive functioning in adolescents. Curr Drug Abuse Rev. 2008;1:99–111.

    Google Scholar 

  72. 72.

    Repp K, Raich A. Marijuana and health: a comprehensive review of 20 years of research [Internet]. 2014. Accessed 18 Nov 2018.

  73. 73.

    Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RSE, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci USA. 2012;109:E2657–64.

    CAS  Google Scholar 

  74. 74.

    Kasper S, Caraci F, Forti B, Drago F, Aguglia E. Efficacy and tolerability of hypericum extract for the treatment of mild to moderate depression. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2010;20:747–65.

    CAS  Google Scholar 

  75. 75.

    Galeotti N, Vivoli E, Bilia AR, Bergonzi MC, Bartolini A, Ghelardini C. A prolonged protein kinase C-mediated, opioid-related antinociceptive effect of st John’s Wort in mice. J Pain Off J Am Pain Soc. 2010;11:149–59.

    CAS  Google Scholar 

  76. 76.

    Galeotti N, Vivoli E, Bilia AR, Vincieri FF, Ghelardini C. St. John’s Wort reduces neuropathic pain through a hypericin-mediated inhibition of the protein kinase Cgamma and epsilon activity. Biochem Pharmacol. 2010;79:1327–36.

    CAS  Google Scholar 

  77. 77.

    Galeotti N, Ghelardini C. St. John’s wort reversal of meningeal nociception: a natural therapeutic perspective for migraine pain. Phytomedicine Int J Phytother Phytopharm. 2013;20:930–8.

    CAS  Google Scholar 

  78. 78.

    Rahimi R, Nikfar S, Abdollahi M. Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:118–27.

    CAS  Google Scholar 

  79. 79.

    Whitten DL, Myers SP, Hawrelak JA, Wohlmuth H. The effect of St John’s wort extracts on CYP3A: a systematic review of prospective clinical trials. Br J Clin Pharmacol. 2006;62:512–26.

    CAS  Google Scholar 

  80. 80.

    Niazi M, Hashempur MH, Taghizadeh M, Heydari M, Shariat A. Efficacy of topical Rose (Rosa damascena Mill) oil for migraine headache: a randomized double-blinded placebo-controlled cross-over trial. Complement Ther Med. 2017;34:35–41.

    Google Scholar 

  81. 81.

    Serna-Jiménez CE, del Rio-Sancho S, Calatayud-Pascual MA, Balaguer-Fernández C, Femenía-Font A, López-Castellano A, et al. Development of antimigraine transdermal delivery systems of pizotifen malate. Int J Pharm. 2015;492:223–32.

    Google Scholar 

  82. 82.

    Delavar Kasmaei H, Ghorbanifar Z, Zayeri F, Minaei B, Kamali SH, Rezaeizadeh H, et al. Effects of Coriandrum sativum syrup on migraine: a randomized, triple-blind, placebo-controlled trial. Iran Red Crescent Med J. 2016;18:e20759.

    Google Scholar 

  83. 83.

    Kamali M, Seifadini R, Kamali H, Mehrabani M, Jahani Y, Tajadini H. Efficacy of combination of Viola odorata, Rosa damascena and Coriandrum sativum in prevention of migraine attacks: a randomized, double blind, placebo-controlled clinical trial. Electron Physician. 2018;10:6430–8.

    Google Scholar 

  84. 84.

    Humphrey RW, Brockway-Lunardi LM, Bonk DT, Dohoney KM, Doroshow JH, Meech SJ, et al. Opportunities and challenges in the development of experimental drug combinations for cancer. J Natl Cancer Inst. 2011;103:1222–6.

    CAS  Google Scholar 

  85. 85.

    Nash KM, Shah ZA. Current perspectives on the beneficial role of Ginkgo biloba in neurological and cerebrovascular disorders. Integr Med Insights. 2015;10:1–9.

    Google Scholar 

  86. 86.

    Allais G, D’Andrea G, Maggio M, Benedetto C. The efficacy of ginkgolide B in the acute treatment of migraine aura: an open preliminary trial. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2013;34(Suppl 1):S161–3.

    Google Scholar 

  87. 87.

    Usai S, Grazzi L, Andrasik F, Bussone G. An innovative approach for migraine prevention in young age: a preliminary study. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2010;31(Suppl 1):S181–3.

    Google Scholar 

  88. 88.

    Usai S, Grazzi L, Bussone G. Gingkolide B as migraine preventive treatment in young age: results at 1-year follow-up. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2011;32(Suppl 1):S197–9.

    Google Scholar 

  89. 89.

    Esposito M, Carotenuto M. Ginkgolide B complex efficacy for brief prophylaxis of migraine in school-aged children: an open-label study. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2011;32:79–81.

    Google Scholar 

  90. 90.

    D’Andrea G, Bussone G, Allais G, Aguggia M, D’Onofrio F, Maggio M, et al. Efficacy of Ginkgolide B in the prophylaxis of migraine with aura. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2009;30(Suppl 1):S121–4.

    Google Scholar 

  91. 91.

    Kayama Y, Shibata M, Takizawa T, Ibata K, Shimizu T, Ebine T, et al. Functional interactions between transient receptor potential M8 and transient receptor potential V1 in the trigeminal system: relevance to migraine pathophysiology. Cephalalgia Int J Headache. 2018;38:833–45.

    Google Scholar 

  92. 92.

    Borhani Haghighi A, Motazedian S, Rezaii R, Mohammadi F, Salarian L, Pourmokhtari M, et al. Cutaneous application of menthol 10% solution as an abortive treatment of migraine without aura: a randomised, double-blind, placebo-controlled, crossed-over study. Int J Clin Pract. 2010;64:451–6.

    CAS  Google Scholar 

  93. 93.

    Zargaran A, Borhani-Haghighi A, Faridi P, Daneshamouz S, Kordafshari G, Mohagheghzadeh A. Potential effect and mechanism of action of topical chamomile (Matricaria chamomilla L.) oil on migraine headache: a medical hypothesis. Med Hypotheses. 2014;83:566–9.

    CAS  Google Scholar 

  94. 94.

    Zargaran A, Borhani-Haghighi A, Salehi-Marzijarani M, Faridi P, Daneshamouz S, Azadi A, et al. Evaluation of the effect of topical chamomile (Matricaria chamomilla L.) oleogel as pain relief in migraine without aura: a randomized, double-blind, placebo-controlled, crossover study. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2018;39:1345–53.

    Google Scholar 

  95. 95.

    Cavin C, Delannoy M, Malnoe A, Debefve E, Touché A, Courtois D, et al. Inhibition of the expression and activity of cyclooxygenase-2 by chicory extract. Biochem Biophys Res Commun. 2005;327:742–9.

    CAS  Google Scholar 

  96. 96.

    Bhaskaran N, Shukla S, Srivastava JK, Gupta S. Chamomile: an anti-inflammatory agent inhibits inducible nitric oxide synthase expression by blocking RelA/p65 activity. Int J Mol Med. 2010;26:935–40.

    CAS  Google Scholar 

  97. 97.

    Singh O, Khanam Z, Misra N, Srivastava MK. Chamomile (Matricaria chamomilla L.): an overview. Pharmacogn Rev. 2011;5:82–95.

    CAS  Google Scholar 

  98. 98.

    Georgiadou G, Tarantilis PA, Pitsikas N. Effects of the active constituents of Crocus sativus L., crocins, in an animal model of obsessive-compulsive disorder. Neurosci Lett. 2012;528:27–30.

    CAS  Google Scholar 

  99. 99.

    Hajhashemi V, Ghannadi A, Hajiloo M. Analgesic and anti-inflammatory effects of Rosa damascena hydroalcoholic extract and its essential oil in animal models. Iran J Pharm Res IJPR. 2010;9:163–8.

    Google Scholar 

  100. 100.

    De Marino S, Borbone N, Zollo F, Ianaro A, Di Meglio P, Iorizzi M. New sesquiterpene lactones from Laurus nobilis leaves as inhibitors of nitric oxide production. Planta Med. 2005;71:706–10.

    Google Scholar 

  101. 101.

    Vision. Feverfew [Internet] Open access image. [Internet]. 2005. Accessed 18 Nov 2018.

  102. 102.

    Cebeci Z. Butterbur [Internet]. Accessed 18 Nov 2018.

  103. 103.

    Leimuranta P, Khiroug L, Giniatullin R. Emerging role of (Endo) cannabinoids in migraine. Front Pharmacol. 2018;9:420.

    Google Scholar 

  104. 104.

    Tognetto M, Amadesi S, Harrison S, Creminon C, Trevisani M, Carreras M, et al. Anandamide excites central terminals of dorsal root ganglion neurons via vanilloid receptor-1 activation. J Neurosci Off J Soc Neurosci. 2001;21:1104–9.

    CAS  Google Scholar 

  105. 105.

    Akerman S, Kaube H, Goadsby PJ. Anandamide acts as a vasodilator of dural blood vessels in vivo by activating TRPV1 receptors. Br J Pharmacol. 2004;142:1354–60.

    CAS  Google Scholar 

  106. 106.

    Russo EB. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro Endocrinol Lett. 2008;29:192–200.

    Google Scholar 

  107. 107.

    Juhasz G, Lazary J, Chase D, Pegg E, Downey D, Toth ZG, et al. Variations in the cannabinoid receptor 1 gene predispose to migraine. Neurosci Lett. 2009;461:116–20.

    CAS  Google Scholar 

  108. 108.

    Nyholt DR, Morley KI, Ferreira MAR, Medland SE, Boomsma DI, Heath AC, et al. Genomewide significant linkage to migrainous headache on chromosome 5q21. Am J Hum Genet. 2005;77:500–12.

    CAS  Google Scholar 

  109. 109.

    Akerman S, Holland PR, Lasalandra MP, Goadsby PJ. Endocannabinoids in the brainstem modulate dural trigeminovascular nociceptive traffic via CB1 and “triptan” receptors: implications in migraine. J Neurosci Off J Soc Neurosci. 2013;33:14869–77.

    CAS  Google Scholar 

  110. 110.

    Jeong H-J, Chenu D, Johnson EE, Connor M, Vaughan CW. Sumatriptan inhibits synaptic transmission in the rat midbrain periaqueductal grey. Mol Pain. 2008;4:54.

    Google Scholar 

  111. 111.

    Vaughan CW, Connor M, Bagley EE, Christie MJ. Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro. Mol Pharmacol. 2000;57:288–95.

    CAS  Google Scholar 

  112. 112.

    Kazemi H, Rahgozar M, Speckmann E-J, Gorji A. Effect of cannabinoid receptor activation on spreading depression. Iran J Basic Med Sci. 2012;15:926–36.

    CAS  Google Scholar 

  113. 113.

    Heptinstall S, Groenewegen WA, Spangenberg P, Loesche W. Extracts of feverfew may inhibit platelet behaviour via neutralization of sulphydryl groups. J Pharm Pharmacol. 1987;39:459–65.

    CAS  Google Scholar 

  114. 114.

    Hayes NA, Foreman JC. The activity of compounds extracted from feverfew on histamine release from rat mast cells. J Pharm Pharmacol. 1987;39:466–70.

    CAS  Google Scholar 

  115. 115.

    Pugh WJ, Sambo K. Prostaglandin synthetase inhibitors in feverfew. J Pharm Pharmacol. 1988;40:743–5.

    CAS  Google Scholar 

  116. 116.

    Williams CA, Hoult JR, Harborne JB, Greenham J, Eagles J. A biologically active lipophilic flavonol from Tanacetum parthenium. Phytochemistry. 1995;38:267–70.

    CAS  Google Scholar 

  117. 117.

    Thomet OA, Wiesmann UN, Schapowal A, Bizer C, Simon HU. Role of petasin in the potential anti-inflammatory activity of a plant extract of Petasites hybridus. Biochem Pharmacol. 2001;61:1041–7.

    CAS  Google Scholar 

  118. 118.

    Wang GJ, Shum AY, Lin YL, Liao JF, Wu XC, Ren J, et al. Calcium channel blockade in vascular smooth muscle cells: major hypotensive mechanism of S-petasin, a hypotensive sesquiterpene from Petasites formosanus. J Pharmacol Exp Ther. 2001;297:240–6.

    CAS  Google Scholar 

  119. 119.

    Volfe Z, Dvilansky A, Nathan I. Cannabinoids block release of serotonin from platelets induced by plasma from migraine patients. Int J Clin Pharmacol Res. 1985;5:243–6.

    CAS  Google Scholar 

  120. 120.

    Formukong E, Garland LG, Evans AT, Evans FJ. Inhibition of A23187 induced release of CTB4 in mouse blood in vivo and human polymorphonuclear cells in vitro by analgesic cannabidiol. Phytother Res. 1991;5:258–61.

    CAS  Google Scholar 

  121. 121.

    Johnson ES, Kadam NP, Hylands DM, Hylands PJ. Efficacy of feverfew as prophylactic treatment of migraine. Br Med J Clin Res Ed. 1985;291:569–73.

    CAS  Google Scholar 

  122. 122.

    Murphy JJ, Heptinstall S, Mitchell JR. Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet. 1988;2:189–92.

    CAS  Google Scholar 

  123. 123.

    Palevitch D, Earon G, Carasso R. Feverfew (Tanacetum parthenium) as a prophylactic treatment for migraine: a double-blind placebo-controlled study. Phytother Res. 1997;11:508–11.

    Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Thilinie Rajapakse.

Ethics declarations


No sources of funding were used to prepare this manuscript.

Conflict of interest

Thilinie Rajapakse and William Jeptha Davenport have no conflicts of interest that are directly relevant to the content of this study.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Rajapakse, T., Davenport, W.J. Phytomedicines in the Treatment of Migraine. CNS Drugs 33, 399–415 (2019).

Download citation